The endometrial cancer data from the ATAC (arimidex, tamoxifen, alone or in combination) trial indicates a protective effect of anastrozole (arimidex) upon the endometrium

被引：0

作者：

Duffy, SR

Greenwood, M

机构：

[1] AstraZeneca, Alderley Pk, England

[2] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2003年 / 82卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

134

引用

页码：S29 / S29

页数：1

共 50 条

[21] The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women. [J].

Baum, M .

BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) :210-210

[22] Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial [J].

Fallowfield, L ;

Cella, D ;

Cuzick, L ;

Francis, S ;

Locker, G ;

Howell, A .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) :4261-4271

[23] Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women:: a sub-protocol of the 'Arimidex™ and Tamoxifen Alone or in Combination' (ATAC) trial [J].

Baum, M ;

Dowsett, M ;

Coibion, M ;

Bianco, AR ;

Cuzick, J ;

George, WD ;

Gray, J ;

Howell, A ;

Houghton, J ;

Williams, N ;

Sloane, J ;

Tobias, J ;

Buzdar, A ;

Anderson, MD ;

Jackson, I ;

Sahmoud, T ;

Gallagher, J ;

Webster, A ;

Gangji, D ;

Petrakova, K ;

Konopasek, B ;

Mares, P ;

Vodvarka, P ;

Alcazar, A ;

Campos, O ;

Maxwell, A ;

Goedhals ;

Hacking, D ;

Landers, G ;

Smith, L ;

Vorobiof, DA ;

Werner, ID ;

Blamey, R ;

Coleman, R ;

Grieve, RJ ;

Hickish, T ;

Howell, A ;

Nicholls, JC ;

Nicholson, S ;

Raymond, S ;

Salman, A ;

Blum, J ;

Clark, R ;

Lyss, A ;

Miletello, G ;

Sternberg, J ;

Forbes, J ;

Coibion, M ;

Nabholtz, JM ;

Guastalla, JP .

BRITISH JOURNAL OF CANCER, 2001, 85 (03) :317-324

[24] Beneficial side-effect profile of anastrozole compared with tamoxifen confirmed by additional 7 months of exposure data: a safety update from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial [J].

Sainsbury, R .

BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 :S156-S156

[25] Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial [J].

British Journal of Cancer, 2001, 85 :317-324

[26] Efficacy data from the ATAC ("arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment [J].

不详 .

BREAST, 2005, 14 :S51-S51

[27] Clinical features of joint symptoms observed in the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. [J].

Buzdar, A. U. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :15S-15S

[28] Impact of age on gynaecological adverse events: data from the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial on behalf of the ATAC Trialists' Group [J].

Disller, Wolfgang .

ANNALS OF ONCOLOGY, 2004, 15 :64-65

[29] Tolerability of anastrozole (A) compared with tamoxifen (T): Mature data in the adjuvant setting - Data reported on behalf of the ATAC ('arimidex', tamoxifen, alone or in combination) trialists' group [J].

Mansel, Robert .

ANNALS OF ONCOLOGY, 2006, 17 :94-94

[30] Fewer gynaecological adverse events (AEs), gynaecological interventions, endometrial changes and abnormalities with anastrozole than with tamoxifen: findings from the ATAC ('Arimidex', Tarmoxifen, Alone or in Combination) trial [J].

Distler, W. .

BREAST, 2007, 16 :S45-S46

← 1 2 3 4 5 →